Emergent BioSolutions
 |
|
| Public company | |
| Traded as | : EBS S&P 600 Component |
| Founded | 1998 |
| Headquarters | Gaithersburg, Maryland |
|
Key people
|
Daniel J. Abdun-Nabi (CEO) Fuad El-Hibri (Executive Chairman of the Board of Directors) Daniel J. Abdun-Nabi (President and Chief Executive Officer) |
| Revenue |
 US $445-$500 million (2014) |
|
US $42.8 million (2014) |
|
| Profit |
US $53-$55 million (2014) |
| Website | Official website |
|
Footnotes / references |
|
| Acquisition history |
|---|
|
Emergent BioSolutions is a multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. It develops vaccines and antibody therapeutics for infectious diseases, oncology and autoimmune disorders, and provides medical devices for biodefense purposes.
Among the company's notable products is BioThrax (Anthrax Vaccine Adsorbed), the only anthrax vaccine licensed by the U.S. Food and Drug Administration (FDA). The company also manufactures pharmaceuticals for adults and children with acute blood disorders, people undergoing certain liver transplants, palliative care for chemo or radiation therapy patients, hemophilia B and a varicella (Chickenpox) vaccine for high risk patients.
The company has two divisions: a Biodefense division for medical countermeasures and a Biosciences division to treat infectious disease, autoimmune diseases, and cancer.
Fuad El-Hibri, the founder of the company and former CEO, led the company since its founding as BioPort Inc. until his retirement on April 1, 2012. El-Hibri continues to serve as the executive chairman of Emergent BioSolutions’ board of directors.
According to the U.S. National Library of Medicine, BioThrax was first made available in 1970.BioThrax (Anthrax Vaccine Adsorbed), a vaccine licensed by the U.S. Food and Drug Administration. Following a study by scientists from the Centers for Disease Control and Prevention, on December 19, 2008, Emergent received final FDA licensing for use of BioThrax five doses for intramuscular injection. Later in 2009, Emergent received approval from the FDA to extend the shelf life of its anthrax vaccine from three to four years. BioThrax was approved for distribution in the United States. BioThrax has received marketing approval in India, Singapore, and Germany.
The FDA gave BioThrax an "orphan drug" designation in April 2014. The FDA gives that status to drugs that are used to treat rare diseases. BioThrax is the only anthrax vaccine licensed by the FDA.
As of April 2014, Emergent has sold over 66 million doses of BioThrax to the U.S. government. Three million U.S. military personnel have received the BioThrax vaccine.
...
Wikipedia